

Furosemide (Frusemide)

Newborn use only

2018

Alert											
Indication	Heart failure. Fluid overload. Short-term treatment in infants with or developing chronic lung disease. Oliguric renal failure. Diuresis renography.										
Action	Potent loop diuretic. Inhibits sodium and chloride absorption in the ascending limb of the loop of Henle and in the proximal and the distal tubules. Furosemide causes urinary losses of water, sodium (increases fractional excretion of sodium by 20–25%), ² potassium and chloride. Urinary losses of calcium and magnesium and urinary pH are increased.										
Drug Type	Loop diuretic.										
Trade Name	IV: Furosemide Sandoz Injection, Furosemide-Clarix, Lasix High Dose Concentrate, Lasix Solution. [Excipients: Sodium hydroxide, sodium chloride and water for injection]. Oral: Lasix oral solution. Note: Contains 12.7% v/v alcohol. [Other Excipients: Sorbitol, glycerol, sodium hydroxide, methyl hydroxybenzoate, propyl hydroxybenzoate, quinoline yellow, sunset yellow FCF, orange flavour, purified water]										
Presentation	IV: 20 mg/2 mL, 40 mg/4 mL or 250 mg/25 mL Oral: 10 mg/mL, 30 mL Note: Commercial preparation “Lasix” contains 12.7% v/v alcohol. Non-alcohol containing suspension can be compounded by local pharmacy.										
Dosage / Interval	IV or PO* : 1 to 2 mg/kg/dose. Dose interval as follows: <table border="1" style="margin-left: 20px;"> <thead> <tr> <th>Corrected gestational age/Postmenstrual age</th> <th>Interval</th> </tr> </thead> <tbody> <tr> <td>Preterm infant ≤ 33 weeks</td> <td>Every 24 hours</td> </tr> <tr> <td>Preterm infant > 33 weeks</td> <td>12–24 hours</td> </tr> <tr> <td>Term infant 0–30 days</td> <td>Every 12 hours</td> </tr> <tr> <td>Term infant > 30 days</td> <td>8–12 hours</td> </tr> </tbody> </table> <p>*PO: Dose may be increased up to maximum 6 mg/kg/dose in term infants with heart failure.</p> <p>IV Infusion: 0.05 to 0.2 mg/kg/hour increased to maximum 0.4 mg/kg/hour if urine output < 1 mL/kg/hour.</p> <p>Diuresis renography: 1 mg/kg stat.</p>	Corrected gestational age/Postmenstrual age	Interval	Preterm infant ≤ 33 weeks	Every 24 hours	Preterm infant > 33 weeks	12–24 hours	Term infant 0–30 days	Every 12 hours	Term infant > 30 days	8–12 hours
Corrected gestational age/Postmenstrual age	Interval										
Preterm infant ≤ 33 weeks	Every 24 hours										
Preterm infant > 33 weeks	12–24 hours										
Term infant 0–30 days	Every 12 hours										
Term infant > 30 days	8–12 hours										
Maximum dose	IV: 2 mg/kg/dose IV infusion: 0.4 mg/kg/hour Oral: 6 mg/kg/dose										
Route	IV or oral										
Preparation/Dilution	IV bolus: Give undiluted. If dilution required draw up 0.5mL (5 mg of furosemide) and add 9.5mL sodium chloride 0.9% to make a final volume of 10 mL with a concentration of 0.5 mg/mL. IV infusion: Single-strength infusion: Draw up 0.5 mL/kg (5 mg/kg of furosemide) and make up to 10 mL with sodium chloride 0.9% or glucose 5% or glucose 10% or glucose 20% to make a 0.5 mg/kg/mL solution. Infusing at a rate of 0.1 mL/hour = 0.05 mg/kg/hour. Double-strength infusion: Draw up 1 mL/kg (10 mg/kg of furosemide) and make up to 10 mL with sodium chloride 0.9% or glucose 5% or glucose 10% or glucose 20% to make a 1 mg/kg/mL solution. Infusing at a rate of 0.1 mL/hour = 0.1 mg/kg/hour. Oral: Use as supplied undiluted.										

Furosemide (Frusemide)

Newborn use only

2018

Administration	IV bolus over 2–4 minutes: maximum rate not to exceed 0.5 mg/kg/minute or 4 mg/minute. For diuresis renography – dose should be given as a push. ¹ IV infusion: Via syringe pump Oral: Solution may be administered without regard to feeds.
Monitoring	Urine output, weight, serum sodium and potassium. Screening for nephrocalcinosis may be required for preterm infants on prolonged therapy.
Contraindications	Known hypersensitivity to furosemide. Severe hypokalaemia, hyponatraemia, hypovolaemia, dehydration or hypotension must be regarded as contraindications until serum electrolytes, fluid balance and blood pressure have been restored to normal levels. Severe jaundice at risk of bilirubin encephalopathy.
Precautions	Commercially available oral furosemide solution contains ethanol and 2 mg/kg/day of solution equates to 1.4 mL/kg/week ethanol intake [equivalent to 1 unit alcohol/week for a man weighing 70 kg]. If increasing azotaemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide. Jaundice – furosemide may displace bilirubin from albumin. However, bilirubin displacement is negligible with standard doses.
Drug Interactions	Furosemide can cause the depletion of potassium and magnesium, which can predispose patients to serious cardiac arrhythmias, particularly in the presence of digitalis therapy. The risk of electrolyte depletion is markedly enhanced when 2 diuretics are used in combination. May prolong action of muscle relaxants. Avoid concomitant usage of aminoglycosides to avoid ototoxicity.
Adverse Reactions	Furosemide is associated with renal losses of calcium, sodium, chloride and potassium. Prolonged and higher doses of furosemide are associated with ototoxicity and nephrocalcinosis.
Compatibility	Fluids: Glucose 5%, glucose 10%, glucose 20%, sodium chloride 0.9% Y-site: Amifostine, amikacin, anidulafungin, aztreonam, bivalirudin, ceftaroline fosamil, dexmedetomidine, doripenem, foscarnet, granisetron, heparin sodium, hydrocortisone sodium succinate, levosimendan, linezolid, lorazepam, metoprolol, piperacillin-tazobactam (EDTA-free), potassium chloride, remifentanyl, sodium nitroprusside, tirofiban, tobramycin.
Incompatibility	Fluids: No information. Variable compatibility with parenteral nutrition solutions. Y-site: Atracurium, azithromycin, benztropine, buprenorphine, caffeine citrate, caspofungin, chlorpromazine, ciprofloxacin, dolasetron, droperidol, eptifibatide, erythromycin, esmolol, filgrastim, fluconazole, gentamicin, glycopyrrolate, haloperidol lactate, hyaluronidase, hydralazine, ketamine, labetalol, metaraminol, metoclopramide, midazolam, milrinone, moxifloxacin, mycophenolate mofetil, ondansetron, pancuronium, pentamidine, pethidine, phentolamine, phenylephrine, promethazine, protamine, quinine, rocuronium, vancomycin, vasopressin, vecuronium, verapamil.
Stability	Do not use if solution is discoloured. Diluted IV solution: Stable for 24 hours at 2–25°C (preferred storage is 2-8°C). Oral solution: Commercial preparation “Lasix” - Discard 8 weeks after opening. Compounded suspension – 14 day expiry.
Storage	Vial: Store below 25°C. Protect from light. Occasionally crystal deposits may be seen when ampoules are stored at low temperatures. Dissolve crystals by warming to 40°C and injection may be used. Discard solutions that are yellow. Oral solution:

Furosemide (Frusemide)

Newborn use only

2018

	Commercial preparation - store below 25°C Compounded suspension – refrigerated at 2-8°C
Special Comments	<p>Loop diuretics are preferred for initial treatment of heart failure as they have a greater effect on sodium excretion compared to distal diuretics.²</p> <p>Potassium deficits can be corrected by the short-term use of potassium supplements. Concomitant administration of a potassium-retaining agent such as spironolactone can prevent potassium depletion in most infants taking a loop diuretic.</p> <p>Alternate day dosing may be considered to reduce the risk of electrolyte and mineral abnormalities.</p> <p>Plasma $t_{1/2}$ of furosemide is 7.7–26.8 hours in neonates. It is longer in immature infants (mean $t_{1/2}$ > 20 hours).²² The $t_{1/2}$ is prolonged by renal and hepatic insufficiency.</p> <p>Blood concentrations exceeding 0.05 mg/mL may be associated with ototoxicity.</p>
Evidence summary	Refer to full version.
References	Refer to full version.

Original version Date: 18/07/2016	Author: NMF Consensus Group
Current Version number: 1.2	Current Version Date: 19/04/2018
Risk Rating: Medium	Due for Review: 19/04/2021
Approval by: As per Local policy	Approval Date:

Authors Contribution

Original author/s	David Osborn
Revision author/s	David Osborn
Expert review	-
Evidence Review	David Osborn
Nursing Review	Eszter Jozsa
Pharmacy Review	Mariella De Rosa, Jing Xiao
Final content and editing review of the original	Ian Whyte
Electronic version	Mariella De Rosa, Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty